Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Coherus Oncology (NASDAQ: CHRS) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30 a.m. PT.
The presentation and Q&A will stream via webcast and a link will be posted on the company's Investor Events Calendar at https://investors.coherus.com/events-presentations. The webcast replay will be available through February 13, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – CHRS
In the Jan 6 session, CHRS declined 5.56%, reflecting a notable negative market reaction. Argus tracked a peak move of +6.3% during that session. Our momentum scanner triggered 21 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 08 | Clinical survival data | Positive | +6.7% | Reported six-year JUPITER-02 data showing markedly improved overall survival with LOQTORZI. |
| Nov 07 | Clinical biomarker update | Positive | -10.1% | Presented detailed CHS-114 biomarker and safety data in HNSCC at SITC 2025. |
| Nov 06 | Quarterly earnings | Negative | -4.8% | Released Q3 2025 results showing LOQTORZI-driven revenue growth but continued net loss. |
| Nov 06 | Leadership appointment | Positive | -4.8% | Announced new Chief Strategy and Corporate Affairs Officer to support oncology focus. |
| Oct 30 | Earnings scheduling | Neutral | -1.7% | Set date and webcast details for upcoming Q3 2025 financial results announcement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news shows mixed alignment: strong positive clinical data and earnings updates sometimes produced selling pressure, while other clinical and informational releases aligned with price gains or modest declines.
Over the last few months, Coherus reported several key milestones. On Oct 30, 2025, it scheduled Q3 results and a business update for Nov 6. That day’s earnings release showed $11.6M in Q3 2025 revenue from continuing operations and a net loss of $(44.5M), coinciding with a -4.79% move. Also on Nov 6, the company added a Chief Strategy and Corporate Affairs Officer, again tied to a -4.79% reaction. Later, multiomic biomarker data for CHS-114 on Nov 7 saw a -10.07% move despite detailed positive immunologic activity. In contrast, six-year JUPITER-02 survival data for LOQTORZI on Dec 8 aligned with a +6.67% gain. Today’s conference participation fits within this backdrop of active clinical and corporate communication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Pacific Time. The presentation and Q&A session will be accessible via webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/events-presentations.
This webcast will be available for replay until February 13, 2026.
About Coherus Oncology
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as through its partners, driving sales multiples and synergies from proprietary combinations.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, and esophageal cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
For more information about LOQTORZI, including the U.S. Prescribing Information and important safety information, please visit www.loqtorzi.com.
LOQTORZI® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.
Coherus Oncology Contact Information:
For Investors:
Carrie Graham
VP, Investor Relations & Advocacy
IR@coherus.com
